Dr. Reddy's Laboratories Ltd. stock fell after the generic drugmaker reported first-quarter fiscal 2027 earnings and revenue that missed Wall Street estimates, compounded by concerns over potential US tariffs on imported generic drugs. The company reported earnings of 6 cents per share, missing the analyst consensus estimate of 17 cents. Revenue declined to $853 million from $903 million a year earlier, falling short of the consensus estimate of $925.53 million. Dr. Reddy's shares were down 8.28% at $11.53 at the time of publication.

Financial Performance Breakdown

The decline in revenue was driven by a drop in specific segments. Generic drug sales fell 5% year over year to 71.99 billion Indian rupees, or about $746 million. Conversely, active pharmaceutical ingredient (API) sales rose 4% to 8.52 billion Indian rupees, or about $89 million.

Operational Challenges

Co-Chairman and Managing Director G.V. Prasad stated that the performance reflected the expected transition beyond lenalidomide revenues, along with an unexpected impact related to semaglutide API. He noted that the underlying base business continued to deliver healthy double-digit growth across all key geographies. The company identified that certain semaglutide batches were out of specification due to an issue with the API used in the product.

Management Guidance

Following the earnings release, management provided detailed forward-looking guidance across several key operational and financial parameters during a conference call.

Regulatory and Trade Environment

Management commented that relocating manufacturing to the United States immediately is not practical given the current tariff environment. This follows US President Donald Trump's announcement regarding a phased tariff plan for generic drugs imported into the US. Trump stated that generic drugs would remain exempt from tariffs until August 2028, after which tariffs would be raised to 100% for one year and 200% thereafter. The policy aims to push pharmaceutical companies to move generic drug manufacturing to the United States.

Dr. Reddy's Laboratories Ltd. recorded a notable block trade on the National Stock Exchange, with approximately 130,807 shares transacted in a single deal. The trade was executed at a price of Rs. 1246.50 per share, aggregating to a total transaction value of Rs. 16.31 crores.

Block Trade Details

The following table summarises the key parameters of the block trade recorded for Dr. Reddy's Laboratories on the NSE:

Block trades of this nature typically involve large institutional participants and are executed outside the regular order book to minimise market impact. The transaction in Dr. Reddy's Laboratories reflects significant movement in the stock at the institutional level.